My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.00 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,...

Via Benzinga

NASDAQ:BMRN is showing decent growth, but is still valued reasonably. ↗

January 14, 2025

Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗

January 08, 2025

Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.

Via Benzinga

Topics ETFs

10 Magnificent Stocks That Can Make You Richer in 2025 ↗

January 03, 2025

A new year brings with it new opportunities to grow your wealth on Wall Street.

Via The Motley Fool

NASDAQ:BMRN, a growth stock which is not overvalued. ↗

December 24, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

The Latest Analyst Ratings For Biomarin Pharmaceutical ↗

December 12, 2024

Via Benzinga

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical ↗

November 15, 2024

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 12, 2025

Via Benzinga

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

February 04, 2025

NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

NASDAQ:BMRN is an undervalued gem with solid fundamentals. ↗

January 27, 2025

Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗

November 06, 2024

Via Benzinga

In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical ↗

October 30, 2024

Via Benzinga

A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast ↗

October 28, 2024

Via Benzinga

NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases. ↗

December 27, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

December 02, 2024

Despite its growth, NASDAQ:BMRN remains within the realm of affordability.

Via Chartmill

When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

November 22, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

November 22, 2024

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

Via MarketBeat

NASDAQ:BMRN stands out as a growth opportunity that won't break the bank. ↗

November 11, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is showing decent growth, but is still valued reasonably.

Via Chartmill

CAMP4 Analyst Highlights Rare Disease Platform Potential ↗

November 05, 2024

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

Via Benzinga

Topics Initial Public Offering

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

October 18, 2024

NASDAQ:BMRN is showing good growth, while it is not too expensive.

Via Chartmill

How Is The Market Feeling About Biomarin Pharmaceutical? ↗

October 15, 2024

Via Benzinga

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗

October 30, 2024

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Via Benzinga

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

October 24, 2024

From Monopar Therapeutics Inc.

Via GlobeNewswire

NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals. ↗

October 16, 2024

Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Analyst Expectations For Biomarin Pharmaceutical's Future ↗

October 04, 2024

Via Benzinga

3 Oversold Stocks with Big RSI Rebound Potential

October 03, 2024

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Via MarketBeat

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.